Aldeyra Therapeutics Inc (ALDX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Todd C. Brady |
| Employees: | 10 |
| Web site: | aldeyra.com |
|
131 HARTWELL AVENUE, SUITE 320, LEXINGTON, MA, 02421
781-761-4904
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.
Please log in first to see chart